Teveten (eprosartan mesylate)

SmithKline Beecham

Approval Status
Approved December 1997

Treatment for

Possible similar drugs

Cardiovascular / Cardiology , Diabetes / Endocrinology

Teveten was approved for the treatment of hypertension, as either a monotherapy or for use in combination with other antihypertensives.

Teveten is an angiotensin II antagonist.

Teveten (eprosartan mesylate) Drug Information

The Teveten (eprosartan mesylate) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top